FDA 483 - Olympus Corporation of the Americas - March 10, 2022

An FDA inspection of Olympus Corporation of the Americas in San Jose, CA, revealed significant deficiencies in their quality system. The firm failed to establish adequate procedures for medical device reporting, ensure proper employee training on adverse event awareness, and effectively manage corrective and preventive actions. Additionally, issues were noted with complaint handling processes and the validation of software used for complaint management.